COGT - Company ID 0001622229
Cogent Biosciences, Inc. trades as COGT and has a market capitalization of $6.95 B, making it the #1176 largest US-listed company by market value. This page tracks Cogent Biosciences, Inc. through 593 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin compressed from -304.9% to -950.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-21 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-05 |
| Major company event | 8-K | 2026-05-05 |
| Annual report to shareholders | ARS | 2026-04-23 |
| Proxy materials | DEFA14A | 2026-04-23 |
| Proxy statement | DEF 14A | 2026-04-23 |
| Insider trade | 4 | 2026-04-03 |
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference – Cogent Biosciences, Inc.
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress – Cogent Biosciences, Inc.
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results – Cogent Biosciences, Inc.
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting – Cogent Biosciences, Inc.
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 – Cogent Biosciences, Inc.
The largest companies sharing Cogent Biosciences, Inc.'s SEC industry classification (pharmaceutical preparations).
Cogent Biosciences, Inc. (COGT) has a market capitalization of $6.95 B as of 2026-07-09, ranking #1176 among US-listed companies.
In its latest fiscal year Cogent Biosciences, Inc. reported a net loss of $328.94M.